Sotrovimab proves succesful in treating Covid-19 patients

Saeed Al Ameri, 36-year-old Emirati tested positive with COVID-19 earlier this year

Saeed Al Ameri

Saeed Al Ameri

Abu Dhabi: Abu Dhabi Health Services Company, (SEHA) – the UAE’s largest healthcare network, has pioneered the nation’s response to the COVID-19 pandemic, and over the past few months, has effectively supported patients who contracted the virus using Sotrovimab, the world’s newest anti-viral treatment.

Saeed Al Ameri, 36-year-old Emirati tested positive with COVID-19 earlier this year. While quarantining at home, Saeed began experiencing high fever, headaches, and body pain, after which he was immediately admitted to the intensive care unit at Sheikh Khalifa Medical City (SKMC), part of the SEHA network, and prescribed Sotrovimab.

Saeed’s fever soon began to drop, with his overall condition showing remarkable improvement, leading to his discharge within four days. However, soon after his discharge, Al Ameri’s wife and mother’s health began to deteriorate, after which both were immediately transferred to SKMC’s intensive care unit and also received Sotrovimab. Like Saeed, they recuperated and were discharged within four days.

Commenting on his experience, Saeed Al Ameri said: “I am so grateful to the leaders of the UAE for their remarkable response to the pandemic. May the UAE be blessed with health, wellness, security, and safety. The unprecedented healthcare me and my family received from the SKMC team was life-saving, I am forever thankful to the entire team.”

Dr. Anwar Salam, Chief Medical Officer, SEHA, said: “As the cornerstone of the UAE’s healthcare landscape and the frontrunners in the nation’s response to the pandemic, we are empowered to bring pioneering services and treatment methods to our community. Thanks to the Department of Health – Abu Dhabi’s leadership, we were quick to adopt the emergency use of Sotrovimab and it has proven successful, with a number of those who used this treatment after contracting COVID-19 showing positive response in a short timeframe.”

Another patient, Allawi Saleh Ali Al Mansouri, also commented on his experience at SKMC, saying: “Sotrovimab contributed significantly to my recovery from the virus. Shortly after receiving the medication, my condition drastically improved, and I was discharged completely healthy. I thank the medical team for their efforts and outstanding healthcare.”

May Siddiq Mansour, also a recent COVID-19 patient, said: “I pray for the nation’s leaders and healthcare providers to be blessed abundantly for all their hard work in the fight against the pandemic. I’m thankful for the effective treatment provided by the UAE to COVID-19 patients, I recovered almost immediately after receiving Sotrovimab and returned back to normal life.”

Sotrovimab has been approved by the U.S. Food & Drug Administration (FDA) and UAE Ministry of Health & Prevention (MOHAP) for the treatment of COVID-19 under an Emergency Use Authorization (EUA), Developed by the science-led global healthcare company with a proven track-record for providing high quality medicines, vaccines, and consumer healthcare products – GSK, Sotrovimab contributes to reducing the number of cases requiring hospitalization for more than 24 hours and reduces the number of deaths from COVID-19 by up to 85% when given to patients as an early treatment method.


About SEHA:

The Abu Dhabi Health Services Company PJSC–SEHA – is an independent, public joint stock company created to develop the curative activities of the public healthcare system in Abu Dhabi. The company owns and operates all the public hospitals and clinics of the Emirate of Abu Dhabi.

 A swelling in her arm

SEHA is part of ADQ, one of the region’s largest holding companies with a broad portfolio of major enterprises spanning key sectors of Abu Dhabi’s diversified economy.

SEHA is committed to continuous improvement of customer care to recognized international standards and providing the community with world-class healthcare. SEHA operates 13 hospitals with 3,385 beds, 70 ambulatory care, family care and urgent care centers and 3 blood banks. Its facilities accommodate 117,162 inpatients annually and conduct 43,262 surgeries, as well as treating more than five million outpatients. SEHA is one of the largest integrated healthcare providers in the Middle East with more than 18,000 doctors, nurses, ancillary care, and administrative personnel. Learn more at 

Send us your press releases to

© Press Release 2021

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.

More From Press Releases